VI. Hypoglycemia Flashcards
TRUE or FALSE: Survival of the brain, and therefore the individual, requires a virtually continuous supply of glucose from the circulation.
TRUE
Hypoglycemia causes functional brain failure, which is typically corrected after the plasma glucose concentration is raised.
What is the Whipple triad
Symptoms, signs, or both consistent with hypoglycemia
A low reliably measured plasma glucose concentration
Resolution of those symptoms or signs after the plasma glucose concentration is raised
In which population is documentation of Whipple triad particularly important?
Those who do not have insulin- sulfonylurea-, or glinide-treated diabetes because hypoglycemic disorders are uncommon in such individuals
3 sources of glucose
Intestinal absorption following digestion of dietary carbohydrates
Glycenolysis
Gluconeogenesis (from precursors including lactate (and pyruvate), amino acids (especially alanine and glutamine), and, to a lesser extent, glycerol
The only organs that express glucose-6-phosphatase, the enzyme necessary for release of glucose into the circulation, at levels sufficient to permit substantial contributions to the systemic glucose pool
Liver and kidneys
The liver and kidneys also express the enzymes necessary for gluconeogenesis.
Many tissues express the enzymes required to synthesize and hydrolyze glycogen.
The organ that is the main source of net endogenous glucose production (through glycogenolysis and gluconeogenesis)
Liver
Tissues that can take up and store glucose as glycogen, or metabolize glucose to pyruvate, which, among other fates, can be reduced to lactate or transaminated to form alanine
Muscle > Fat
Essentially the sole metabolic fuel for the brain under physiologic conditions
Glucose
Although the adult human brain constitutes only about 2.5% of body weight, its oxidative metabolism accounts for approximately 25% of the basal metabolic rate and more than 50% of whole-body glucose utilization.
During extended fasting, markedly elevated circulating ketone levels can support the majority of the energy needs and reduce its utilization of glucose.
Notably, ketogenesis is suppressed during episodes of insulin-mediated hypoglycemia.
In healthy adults, the physiologic postabsorptive (fasting) plasma glucose concentration ranges from approximately __ to __ mg/dL, with a mean of __ mg/dL.
70 to 110
90
In the postabsorptive steady rate, rates of glucose production and utilization average approximately __ mg/kg per minute.
2.2 mg/kg per minute
Threefold higher in infants (greater brain mass relative to weight)
Predominant source of endogenous glucose production in the postabsorptive state
Liver
TRUE about the effects of insulin on glucose influx into circulation EXCEPT:
a. Decreases glygocenolysis and gluconeogenesis in the liver
b. Decreases gluconeogenesis in the kidneys
c. Increases variable glucose utilization by other tissues (e.g., muscle, fat, liver, kidneys)
d. All of the above are TRUE
C
TRUE about the effects of glucagon on glucose influx into circulation:
a. Increases glygocenolysis and gluconeogenesis in the liver
b. Increases gluconeogenesis in the kidneys
c. Decreases variable glucose utilization by other tissues (e.g., muscle, fat, liver, kidneys)
d. All of the above
A
Glucagon doesn’t affect glucose production in the kidneys nor the rate of glucose clearance by insulin-sensitive tissues
TRUE about the effects of epinephrine on glucose influx into circulation:
a. Increases glygocenolysis and gluconeogenesis in the liver
b. Increases gluconeogenesis in the kidneys
c. Decreases variable glucose utilization by other tissues (e.g., muscle, fat, liver, kidneys)
d. All of the above
D
Average glucose pool (free glucose in the ECF and in cells of certain tissues, primarily the liver)
Average glucose content of glycogen
Average length of time for which preformed glucose can provide a supply of energy
15 to 20 g
70 g
8 hours
Responses of the body to prolonged fasting ~24 to 48 hours
Plasma glucose declines. Hepatic glucogen content falls to less than 10 g
Because amino acids are the main gluconeogenic precursors that result in net glucose formation, muscle protein is degraded.
Glucose utilization by muscle and fat virtually ceases.
As lipolysis and ketogenesis accelerate and circulating ketone levels rise, ketones become a major fuel for the brain.
First, second, and third responses to hypoglycemia
First - Decrease in insulin secretion (primary glucose regulatory factor)
Second - Increase in glucagon secretion (primary glucose conterregulatory factor)
Third - Increase in epinephrine secretion (critical when glucagon is deficient)
Cortisol and growth hormone - NOT critical
Clinical hypoglycemia - that sufficient to cause symptoms and signs - is most convincingly documented by
Whipple triad
What are neuroglycopenic symptoms
Direct result of brain glucose deprivation:
Warm, weak, difficulty thinking/confused, tired/drowsy, faint, dizzy, difficulty speaking, blurred vision
What are neurogenic (or autonomic) symptoms
Largely the result of the perception of physiologic changes caused by the sympathoadrenal discharge triggered by hypoglycemia
Cholinergic: Sweaty, hungry, tingling
Adrenergic: Shaky/tremulous, heart pounding, nervous/anxious
Subjective awareness of hypoglycemia is largely the result of the perception of ___ symptoms
Neurogenic
TRUE or FALSE: The glycemic threshold for a decrease in the cerebral metabolic role of glucose, measured with 11C-glucose PET, is at a higher plasma glucose concentration than the glycemic thresholds for the hormonal and sympathetic responses.
FALSE
The glycemic threshold for a decrease in the cerebral metabolic role of glucose, measured with 11C-glucose PET, is at a LOWER plasma glucose concentration than the glycemic thresholds for the hormonal and sympathetic responses.
Hence, the signaling of glucose regulatory and counterregulatory hormones and sympathetic responses to hypoglycemia are NOT mediated by a decrease in brain glucose metabolism.
Glycemic threshold for:
Decreased insulin
Increased glucagon
Increased epinephrine
Increased cortisol and growth hormone
Symptoms
Decreased cognition
Decreased brain glucose metabolism
Decreased insulin: 80-85 mg/dL
Increased glucagon: 65-70 mg/dL
Increased epinephrine: 65-70 mg/dL
Increased cortisol and growth hormone: 65-70 mg/dL
Symptoms: 50-55 mg/dL –> Prompt behavioral defense (food ingestion)
Decreased cognition: <50 mg/dL –> Compromises behavioral defense
Decreased brain glucose metabolism: <50 mg/dL
What signals the fist, second, and third lines of defense against hypoglycemia
Signals of defense against hypoglycemia:
- Decrease in insulin is signaled primarily by declining glucose levels at the beta cells
- Increase in glucagon is signaled primarily by a decrease in intra-islet insulin
- Increase in epinephrine is signaled by CNS due to falling glucose levels, acting through the hypothalamus
How does epinephrine increase glucose?
Largely by beta2-adrenergic stimulation of hepatic and renal glucose production
Others:
- Limitation of glucose clearance by insulin-sensitive tissues
- Mobilization of gluconeogenic precursors such as lactate and amino acids from muscle and glycerol from fat
- Alpha2-adrenergic limitation of insulin secretion
What limits the magnitude of glycemic response to epinephrine despite alpha2-adrenergic stimulation of insulin secretion?
Beta2-adrenergic stimulation also stimulates insulin secretion
This explains why glycemic sensitivity to epinephrine is increased in patients who cannot increase insulin secretion (e.g., T1DM)
Circulating epinephrine, as well as the plasma norepinephrine, in response to hypoglycemia are derived largely from the
Adrenal medulla
How do recurrent hypoglycemia and poorly controlled diabetes shift the glycemic thresholds for symptoms and signs of hypoglycemia?
They shift to lower plasma glucose concentrations in patients with recurrent hypoglycemia and to higher concentrations in those with poorly controlled diabetes
Glucose concentrations measured in whole blood are approximately 15% ___ (lower/higher) than those in plasma and may be further ___ reduced/increased) if the hematocrit is high
Lower
Reduced
The most common cause of hypoglycemia
Drugs (insulin secretagogues and insulin)
Approximate frequency of hypoglycemia in T1DM patients
Approximately 2 episodes of symptomatic hypoglycemia per week, and roughly 1 episode per year of severe, at least temporarily disabling hypoglycemia, often with seizure or coma
T1DM patients have more frequent hypoglycemia, but for T2DM patients, the incidence of hypoglycemia increases progressively over time as patients approach the absolute endogenous insulin-deficient end of the spectrum of T2DM.
Since T2DM has higher prevalence, most episodes of iatrogenic hypoglycemia, including severe hypoglycemia, occur in persons with T2DM.
TRUE or FALSE: Lower HbA1c levels are associated with increased mortality in patients with T2DM at higher risk of hypoglycemia.
TRUE
TRUE or FALSE: Systematic long-term follow-up of the DCCT patients suggests that recurrent iatrogenic hypoglycemia causes chronic cognitive impairment in young adults.
FALSE
Systematic long-term follow-up of the DCCT patients suggests that recurrent iatrogenic hypoglycemia does not chronic cognitive impairment in young adults, but the possibility that it does so in young children and elderly remains.
Most instances of sudden hypoglycemic death are thought to be the result of ___.
Cardiac arrhythmias triggered by an intense sympathoadrenal response to hypoglycemia
ADA/ES Workgroup on Hypoglycemia definition of hypoglycemia in diabetes
All episodes of abnormally low plasma glucose concentration that expose the individual to potential harm
*It is not possible to define a plasma glucose concentration that categorically defines hypoglycemia.
Recommended definition of clinical hypoglycemia in persons without diabetes
A plasma glucose concentration low enough to cause symptoms or signs
*It is not possible to define a plasma glucose concentration that categorically defines hypoglycemia.
Why was 70 mg/dL chosen as the glucose alert level
1) It approximates the lower limit of the nondiabetic postabsorptive plasma glucose range and the normal glycemic thresholds for activation of physiologic glucose counterregulatory systems.
2) It is low enough to reduce glycemic defenses against subsequent hypoglycemia in nondiabetic persons.
3) It gives the patient time to take action to prevent a clinical hypoglycemic episode.
4) It provides some margin for the limited accuracy of glucose monitoring devices at low plasma glucose concentrations.
International Hypoglycaemia Study Group 3 levels of iatrogenic hypoglycemia in diabetes
Level 1: A glucose alert value of 70 mg/dL or less
Level 2: A glucose level of less than 54 mg/dL, which is sufficiently low to indicate serious clinically important hypoglycemia
Level 3: Severe hypoglycemia as defined by ADA
Definition of the following clinical classifications of hypoglycemia in diabetes:
- Severe hypoglycemia
- Documented symptomatic hypoglycemia
- Asymptomatic hypoglycemia
- Probable symptomatic hypoglycemia
- Pseudohypoglycemia
Severe hypoglycemia - an event requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions (plasma glucose may not be available, but neurologic recovery attributable to restoration of plasma glucose to normal is sufficient evidence that the event was induced by low plasma glucose)
Documented symptomatic hypoglycemia - an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration of <=70 mg/dL
Asymptomatic hypoglycemia - an event NOT accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration of <=70 mg/dL
Probable symptomatic hypoglycemia - an event during which symptoms typical of hypoglycemia are NOT accompanied by a plasma glucose determination but were presumably caused by a plasma glucose concentration <=70 mg/dL
Pseudohypoglycemia - an event during which the persons with diabetes reports any of the typical symptoms of hypoglycemia and interprets those as indicative of hypoglycemia, with a measured plasma glucose concentration that is >70 mg/dL but is approaching that level
What happens with the defenses against hypoglycemia in patients with established T1DM (absolute deficiency of endogenous insulin)?
Insulin concentrations do not decrease in response to therapeutic hyperinsulinemia - First physiologic defense is lost
Despite the presence of functional alpha cells, there is no increase in glucagon - Second defense is lost
The increase in epinephrine secretion, the third physiologic defense against hypoglycemia, is typically attenuated. This is a marker of attenuation of the sympathoadrenal response –> hypoglycemia unawareness
What causes hypoglycemia unawareness / impaired awareness of hypoglycemia?
Largely the result of reduced release of the sympathetic neurotransmitters norepinephrine and acetylcholine
How does Hypoglycemia-Associated Autonomic Failure (HAAF) develop?
Advanced T2DM and T1DM (absolute beta-cell failure) –>
Relative or mild-moderate absolute therapeutic hyperinsulinemia –> Falling glucose levels –>
Beta-cell failure –> No decrease in insulin and no increase in glucagon –>
Episodes of hypoglycemia, together with exercise and sleep –>
HAAF
What is the consequences of HAAF?
1) Decreased adrenomedullary epinephrine response –> Defective glucose counterregulation
2) Decreased sympathetic neural response –> Impaired awareness of hypoglycemia
Both leads to recurrent hypoglycemia (which further attenuates the sympathoadrenal response to falling plasma glucose concentrations)
TRUE or FALSE: The pathophysiology of glucose counterregulation is the same in T1DM and T2DM but with different time courses.
TRUE
In contrast to the compromised defenses in T1DM, defenses against hypoglycemia are intact early in the course of T2DM. However, they become compromised over time.
TRUE about HAAF (as many as may apply):
a. It is a functional form of autonomic failure
b. It is the same as classic diabetic autonomic neuropathy
c. It reduces baroreflex sensitivity and may predispose patients to cardiac arrhythmias
A and C
It is distinct from classic diabetic autonomic neuropathy.
As little as __ to __ weeks of scrupulous avoidance of hypoglycemia reverses impaired awareness of hypoglycemia and improves the attenuated epinephrine component of defective glucose counterregulation in most affected patients.
2 to 3 weeks
3 recognized causes of reversibly attenuated sympathoadrenal response to hypoglycemia (and therefore 3 forms of HAAF)
Antecedent hypoglycemia-related HAAF
Exercise-related HAAF (exemplified by late postexercise hypoglycemia, which typically occurs 6 to 15 hours after strenuous exercise and is often nocturnal)
Sleep-related HAAF (result of further attenuation of the sympathoadrenal reponse to hypoglycemia during sleep)
Part of the brain that is the central integrator of the sympathoadrenal response to hypoglycemia
Hypothalamus
Conventional risk factors for hypoglycemia in diabetes
Absolute or Relative Insulin Excess:
- Insulin or insulin secretagogue doses are excessive, ill-timed, or the wrong type
- Exogenous glucose delivery is decreased (e.g., after missed meals, during the overnight fast)
- Glucose utilization is increased (e.g., during exercise)
- Endogenous glucose production is decreased (e.g., after alcohol ingestion)
- Sensitivity to insulin is increased (e.g., after weight loss, with improved fitness or improved glycemic control, in the middle of the night)
- Insulin clearance is decreased (e.g., with renal failure)
Clinical risk factors for hypoglycemia
- Presence of HAAF
- History of severe hypoglycemia
- Chronic kidney disease
- Long duration of diabetes
- Malnutrition
Risk factors for HAAF
- Absolute endogenous insulin deficiency
- A history of severe hypoglycemia, impaired awareness of hypoglycemia, or both, and recent antecedent hypoglycemia, prior exercise, or sleep
- Aggressive glycemic therapy per se (lower HbA1c levels, lower glycemic goals, or both)